The future of real-world research is now
ESMO is at the forefront of digital oncology, with some initiatives that support oncologists navigating the emerging opportunities in the field of real-world data research
The emerging role of ctDNA in breast cancer
Liquid biopsies hold great promise in precision medicine in breast cancer, as shown by the pioneering work of Prof. Nicholas Turner, recipient of the ESMO Award for Translational Research 2023
Three decades of progress in nasopharyngeal cancer
Tailored management for high-risk locoregional disease, together with more effective immunotherapy combinations are key areas of exploration in nasopharyngeal cancer, according to 2023 ESMO Lifetime Achievement awardee Prof. Anthony Chan
Precision oncology – are we at an inflection point?
At Molecular Analysis for Precision Oncology (MAP) Congress 2023, international experts discuss the future of histology-agnostic drug development and clinical trial design
Innovative approaches in the management of gastrointestinal cancers
Molecular characterisation of tumour subtypes and immunotherapy are key areas attracting researchers’ efforts that may shape the future of clinical practice, according to ESMO President Prof. Andrés Cervantes
Liquid biopsy in colorectal cancer – the time has come?
Recent findings from studies confirm the promises of ctDNA in this setting, but unanswered questions still remain about timing and methodology
Advanced genetic testing is largely inaccessible to cancer patients across Europe
An ESMO study shows that precision oncology is out of reach for the majority of patients, with costs of technologies and reimbursement policies acting as major barriers
Cancer Research
On the horizon of translational research
Tumour agnostic targeted agents and ‘smarter’ dynamic designs are two major areas of interest leading to more patient-centric approaches in cancer care
Early-phase data from targeting HER3 with ADC are encouraging
Some studies presented suggest preliminary activity of patritumab–deruxtecan in patients with HR-positive/HER2-negative disease and triple-negative breast cancer
Extended safety information and PROs data support key trial results in metastatic breast cancer
Data presentations from DESTINY-Breast04, DESTINY-Breast02 and EMERALD trials confirm the value of trastuzumab deruxtecan and elacestrant in this setting, despite moderate drop-out rates for PROs